Opinion

Video

Evidence-Based Sequencing for HER2+ mBC After Progression: Clinical Trial Data and NCCN Guideline Updates

Author(s):

Tiffany A. Traina, MD,VK Gadi, MD, PhD

Key opinion leaders explore various therapeutic options for later-line treatment of HER2-positive metastatic breast cancer, emphasizing the significance of the HER2CLIMB and CLEOPATRA trials, while also drawing comparisons to real-world data to inform clinical decision-making.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Related Content
Neoadjuvant Dostarlimab in dMMR Solid Tumors | Image credit: © Thipphaphone – stock.adobe.com
April 29th 2025

Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors

Ramez N. Eskander, MD, gynecologic oncologist, assistant professor, obstetrics, gynecology, and reproductive sciences, the University of California San Diego Health; Rachel N. Grisham, MD, associate attending physician, Memorial Sloan Kettering Cancer Center; Benjamin Herzberg, MD, assistant professor, medicine, Columbia University Medical Center, oncologist, Herbert Irving Comprehensive Cancer Center; Kelly McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA Health’s David Geffen School of Medicine; Gregory Roloff, MD, hematologist/oncologist, the University of Chicago Medicine
March 31st 2025

Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.
April 26th 2025

The OncFive: Top Oncology Articles for the Week of 4/20

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
February 17th 2025

Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

Reshma Mahtani, DO
April 22nd 2025

Female Leadership and Representation in Oncology Is an Immense ‘Honor and Responsibility’

Nerea Lopetegui-Lia, MD, breast medical oncologist, assistant professor, The Ohio State University Comprehensive Cancer Center—James
April 21st 2025

Fertility and Toxicity Considerations Factor into TNBC Management